Format

Send to:

Choose Destination
See comment in PubMed Commons below
Mater Sci Eng C Mater Biol Appl. 2016 Mar 1;60:511-7. doi: 10.1016/j.msec.2015.12.004. Epub 2015 Dec 4.

Marbofloxacin-encapsulated microparticles provide sustained drug release for treatment of veterinary diseases.

Author information

  • 1Bio/Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 305-600, South Korea.
  • 2Bio/Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 305-600, South Korea; Medicinal and Pharmaceutical Chemistry, University of Science and Technology, Yuseong, Daejeon 305-350, South Korea.
  • 3KBNP, Doosan Venture-Digm 706, 126-1 Pyeongchon Dongan-Gu, Anyang, Gyeonggi, South Korea.
  • 4Department of Immunology, School of Medicine, Konkuk University, 268 Chungwondaero, Chungju-Si, Chungcheongbuk-Do 380-701, South Korea. Electronic address: hanhd@kku.ac.kr.
  • 5Bio/Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 305-600, South Korea; Medicinal and Pharmaceutical Chemistry, University of Science and Technology, Yuseong, Daejeon 305-350, South Korea. Electronic address: bcshin@krict.re.kr.

Abstract

Fluoroquinolone antibiotics with concentration-dependent killing effects and a well-established broad spectrum of activity are used commonly to treat infectious diseases caused by bacteria. However, frequent and excessive administration of these antibiotics is a serious problem, and leads to increased number of drug-resistant bacteria. Thus, there is an urgent need for novel fluoroquinolone antibiotic formulations that minimize the risk of resistance while maximizing their efficacy. In this study, we developed intramuscularly injectable polymeric microparticles (MPs) that encapsulated with marbofloxacin (MAR) and were composed of poly(D,L-lactide-co-glycolic acid) (PLGA) and poloxamer (POL). MAR-encapsulated MP (MAR-MP) had a spherical shape with particle size ranging from 80 μm to 120 μm. Drug loading efficiency varied from 55 to 85% (w/w) at increasing amount of hydrophilic agent, POL. Drug release from MAR-MP demonstrated a significant and sustained increase at increased ratios of POL to PLGA. These results indicate that MAR-MP is an improved drug delivery carrier for fluoroquinolone antibiotics, which can reduce the number of doses needed and sustain a high release rate of MAR for 2-3 days. As a novel and highly effective drug delivery platform, MAR-MP has great potential for use in a broad range of applications for the treatment of various veterinary diseases.

Copyright © 2015. Published by Elsevier B.V.

KEYWORDS:

Marbofloxacin; Microparticle; Sustained drug release; Veterinary disease

PMID:
26706558
[PubMed - in process]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk